Base de dados : MEDLINE
Pesquisa : C04.557.450.590.455 [Categoria DeCS]
Referências encontradas : 7672 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 768 ir para página                         

  1 / 7672 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29429158
[Au] Autor:Sun M; Liu JG; Weng QY; Yu L; Wang J
[Ad] Endereço:Department of Pathology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
[Ti] Título:[Pleomorphic and dedifferentiated leiomyosarcoma: a clinicopathologic analysis].
[So] Source:Zhonghua Bing Li Xue Za Zhi;47(2):87-93, 2018 Feb 08.
[Is] ISSN:0529-5807
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To investigate the clinicopathologic features, differential diagnosis and biological behavior of pleomorphic leiomyosarcoma (PLMS) and dedifferentiated leiomyosarcoma (DLMS). Forty-nine cases were collected from November 2007 to December 2016, including eight that diagnosed at Fudan University Shanghai Cancer Center, and 41 consultation cases. The clinical findings and pathologic features were reviewed. Immunophenotype was obtained in 33 cases and follow-up information was available in 38 cases. There were 22 males and 27 females with ages ranging from 24 to 83 years (mean 52.5 years). Fifteen cases occurred in extremities, 14 in deep body cavity, 11 in the trunk, 4 in the head and neck, 2 in the bladder, and 1 each in the inguinal region, perineum and femoral vein, respectively. Tumor sizes ranged from 3 to 30 cm (mean 9.1 cm). The tumors were composed of at least small foci of typical leiomyosarcoma (LMS) and areas of high-grade pleomorphic/undifferentiated sarcoma. The typical LMS component showed the characteristic morphology of smooth muscle differentiation and was low to intermediate grade in most cases. Pleomorphic areas were mainly composed of atypical spindle and polygonal cells admixed with variable large, bizarre atypical cells and multinuclear giant cells, mostly mimicking undifferentiated pleomorphic sarcoma. The pleomorphic and leiomyosarcomatous areas were usually intermixed, but the demarcation may be distinct or gradual in some cases. The classical LMS component was positive for at least one myogenic marker: α-SMA in 97.0%(32/33), desmin in 72.7%(24/33), H-caldesmon in 90.9% (20/22), MSA in 14/16, and calponin in 15/15 of cases. The pleomorphic sarcoma component was reactive for at least one myogenic marker in 87.9% (29/33) of cases, usually showing focal and less intense immunoreactivity than classical LMS component: α-SMA was positive in 81.8%(27/33), desmin in 48.5%(16/33), H-caldesmon in 72.7% (16/22), MSA in 12/16, and calponin in 11/15 of cases. Based on staining for muscle markers in the pleomorphic component, 29 cases were designated as PLMS, 4 as DLMS. Ki-67 index ranged from 15% to 70% (mean 40%). Follow-up data was available in 38 cases (77.6%), of which 11 patients (28.9%) died of disease, 12 patients were alive with unresectable or recurrent disease, 14 patients were alive with no evidence of disease and another one died of unrelated cause. The median disease-free and overall survival was 6 and 10 months respectively. Twelve patients exhibited local recurrence and 11 developed metastases. The median interval to progression was 8 months. The identification of areas of typical LMS is crucial for accurate diagnosis of PLMS and DLMS. Both PLMS and DLMS show more aggressive behavior and poorer prognosis than ordinary LMS.
[Mh] Termos MeSH primário: Leiomiossarcoma/patologia
Neoplasias Cutâneas/patologia
[Mh] Termos MeSH secundário: Actinas/análise
Adulto
Idoso
Idoso de 80 Anos ou mais
Biomarcadores Tumorais/análise
Proteínas de Ligação ao Cálcio/análise
Proteínas de Ligação a Calmodulina/análise
Diferenciação Celular
China
Desmina/análise
Diagnóstico Diferencial
Extremidades
Feminino
Histiocitoma Fibroso Maligno/química
Histiocitoma Fibroso Maligno/patologia
Seres Humanos
Imuno-Histoquímica
Imunofenotipagem
Leiomiossarcoma/química
Masculino
Proteínas dos Microfilamentos/análise
Meia-Idade
Recidiva Local de Neoplasia
Neoplasias Cutâneas/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ACTA2 protein, human); 0 (Actins); 0 (Biomarkers, Tumor); 0 (Calcium-Binding Proteins); 0 (Calmodulin-Binding Proteins); 0 (Desmin); 0 (Microfilament Proteins); 0 (calponin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180213
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0529-5807.2018.02.002


  2 / 7672 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29403338
[Au] Autor:Rasool N; Lefebvre DR; Latina MA; Dunn IF; Santagata S; Freitag SK; Cestari DM
[Ad] Endereço:Edward Harkness Eye Institute, Columbia University, New York.
[Ti] Título:Orbital leiomyosarcoma metastasis presenting prior to diagnosis of the primary tumor.
[So] Source:Digit J Ophthalmol;23(4):22-26, 2017.
[Is] ISSN:1542-8958
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Leiomyosarcomas, neoplasms of smooth muscle, are rarely found within the orbit. Orbital leiomyosarcoma may be primary, metastatic, or secondary to radiation. When they are metastatic, patients almost exclusively have a history of a primary leiomyosarcoma, often occurring in the spermatic cord, skin, gastrointestinal tract, or the uterus. We present the case of 48-year-old woman who presented with a metastatic orbital leiomyosarcoma, which was identified before the primary tumor.
[Mh] Termos MeSH primário: Leiomiossarcoma/secundário
Neoplasias Orbitárias/patologia
Neoplasias Uterinas/secundário
[Mh] Termos MeSH secundário: Biópsia
Diagnóstico Diferencial
Feminino
Seres Humanos
Leiomiossarcoma/diagnóstico
Imagem por Ressonância Magnética
Meia-Idade
Metástase Neoplásica
Tomografia por Emissão de Pósitrons
Neoplasias Uterinas/diagnóstico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180207
[St] Status:MEDLINE
[do] DOI:10.5693/djo.02.2017.02.004


  3 / 7672 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28744668
[Au] Autor:Sano A; Yotsumoto T
[Ad] Endereço:Department of Thoracic Surgery, Chigasaki Municipal Hospital, Honson 5-15-1, Chigasaki, Kanagawa, 253-0042, Japan. sanoa-tky@umin.ac.jp.
[Ti] Título:Single-port thoracoscopic lung wedge resection using the Endo GIA Radial Reload.
[So] Source:Surg Today;48(2):248-251, 2018 Feb.
[Is] ISSN:1436-2813
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:The GIA Radial Reload is a surgical stapler with a curved cut line that is perpendicular to the direction of instrument insertion. We used the GIA Radial Reload in three cases of single-port thoracoscopic lung wedge resection. The operations were performed through a 3.0-4.5-cm incision. For the first stapler, we selected the GIA Radial Reload. The orientation of this device's cut line enabled us to easily cut the lung behind the lesion during single-port thoracoscopic surgery.
[Mh] Termos MeSH primário: Pneumonectomia/instrumentação
Grampeadores Cirúrgicos
Toracoscopia/instrumentação
[Mh] Termos MeSH secundário: Idoso
Fístula Arteriovenosa/cirurgia
Feminino
Seres Humanos
Leiomiossarcoma/secundário
Leiomiossarcoma/cirurgia
Neoplasias Pulmonares/secundário
Neoplasias Pulmonares/cirurgia
Meia-Idade
Pneumonectomia/métodos
Artéria Pulmonar/anormalidades
Veias Pulmonares/anormalidades
Toracoscopia/métodos
Neoplasias Uterinas/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.1007/s00595-017-1572-0


  4 / 7672 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463157
[Au] Autor:Schaefer IM; Hornick JL; Barysauskas CM; Raut CP; Patel SA; Royce TJ; Fletcher CDM; Baldini EH
[Ad] Endereço:Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
[Ti] Título:Histologic Appearance After Preoperative Radiation Therapy for Soft Tissue Sarcoma: Assessment of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group Response Score.
[So] Source:Int J Radiat Oncol Biol Phys;98(2):375-383, 2017 06 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To critically assess the prognostic value of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) response score and define histologic appearance after preoperative radiation therapy (RT) for soft tissue sarcoma (STS). METHODS AND MATERIALS: For a cohort of 100 patients with STS of the extremity/trunk treated at our institution with preoperative RT followed by resection, 2 expert sarcoma pathologists evaluated the resected specimens for percent residual viable cells, necrosis, hyalinization/fibrosis, and infarction. The EORTC response score and other predictors of recurrence-free survival (RFS) and overall survival (OS) were assessed by Kaplan-Meier and proportional hazard models. RESULTS: Median tumor size was 7.5 cm; 92% were intermediate or high grade. Most common histologies were unclassified sarcoma (34%) and myxofibrosarcoma (25%). Median follow-up was 60 months. The 5-year local recurrence rate was 5%, 5-year RFS was 68%, and 5-year OS was 75%. Distribution of cases according to EORTC response score tiers was as follows: no residual viable tumor for 9 cases (9% pathologic complete response); <1% viable tumor for 0, ≥1% to <10% for 9, ≥10% to <50% for 44, and ≥50% for 38. There was no association between EORTC-STBSG response score and RFS or OS. Conversely, hyalinization/fibrosis was a significant independent favorable predictor for RFS (hazard ratio 0.49, P=.007) and OS (hazard ratio 0.36, P=.02). CONCLUSION: Histologic evaluation after preoperative RT for STS showed a 9% pathologic complete response rate. The EORTC-STBSG response score and percent viable cells were not prognostic. Hyalinization/fibrosis was associated with favorable outcome, and if validated, may become a valid endpoint for neoadjuvant trials.
[Mh] Termos MeSH primário: Sarcoma/patologia
Sarcoma/radioterapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Sobrevivência Celular
Intervalo Livre de Doença
Feminino
Fibrossarcoma/mortalidade
Fibrossarcoma/patologia
Fibrossarcoma/radioterapia
Fibrossarcoma/cirurgia
Fibrose/patologia
Seguimentos
Seres Humanos
Infarto/patologia
Estimativa de Kaplan-Meier
Leiomiossarcoma/mortalidade
Leiomiossarcoma/patologia
Leiomiossarcoma/radioterapia
Leiomiossarcoma/cirurgia
Lipossarcoma/mortalidade
Lipossarcoma/patologia
Lipossarcoma/radioterapia
Lipossarcoma/cirurgia
Masculino
Meia-Idade
Necrose/patologia
Neoplasia Residual
Modelos de Riscos Proporcionais
Sarcoma/mortalidade
Sarcoma/cirurgia
Fatores de Tempo
Resultado do Tratamento
Carga Tumoral
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  5 / 7672 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29443772
[Au] Autor:Yang J
[Ti] Título:Primary leiomyosarcoma in the colon: A case report.
[So] Source:Medicine (Baltimore);97(7):e9923, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Leiomyosarcoma (LMS) is a common type of soft tissue sarcoma. Primary colonic LMS in general is a very rare entity, accounting for 1% to 2% of gastrointestinal malignancies. PATIENT CONCERNS: We report a case of 55-year-old female who presented with a sudden onset of sharp right lower quadrant abdominal pain. Electronic colonoscopy showed a normal lumen. However, an abdominal computed tomography scan revealed a mass of soft tissue attenuation inseparable from the ascending colon which appeared as a gastrointestinal stromal tumor (GIST). DIAGNOSES: It is important to diagnose LMS definitively by immunohistochemical profiling of smooth muscle actin, desmin, and CD34. INTERVENTIONS: She underwent laparotomy and right hemicolectomy, and histology confirmed a colonic LMS. The patient received no oncological treatment after surgery. OUTCOMES: No recurrence or metastasis was observed at 5 months postoperatively. It is crucial to identify colonic LMS precisely based on immunohistochemistry, and thereby distinguish it from GIST. LESSONS: Further investigation on LMS cases so far is required to establish standard treatment strategies.
[Mh] Termos MeSH primário: Neoplasias do Colo/diagnóstico
Leiomiossarcoma/diagnóstico
[Mh] Termos MeSH secundário: Colectomia
Neoplasias do Colo/diagnóstico por imagem
Neoplasias do Colo/cirurgia
Colonoscopia
Diagnóstico Diferencial
Feminino
Tumores do Estroma Gastrointestinal/diagnóstico
Seres Humanos
Imuno-Histoquímica
Leiomiossarcoma/diagnóstico por imagem
Leiomiossarcoma/cirurgia
Meia-Idade
Tomografia Computadorizada por Raios X
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009923


  6 / 7672 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29365374
[Au] Autor:Wen YH; Wen WP; Wang ZF; Zhu XL; Jiang AY; Chai LP; Lei WB
[Ad] Endereço:Otorhinolaryngology Hospital, the First Affliated Hospital of Sun Yatsen University, Guangzhou Key Laboratory of Otorhinolaryngology, Guangzhou 510080, China.
[Ti] Título:[Clinical application of supraclavicular flap for oncologic reconstruction of hypopharynx and upper esophagus].
[So] Source:Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi;53(1):16-20, 2018 Jan 07.
[Is] ISSN:1673-0860
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To assess the efficacy of supraclavicular artery island flap (SCAIF) for the reconstruction of hypopharynx and upper esophagus. The SCAIF procedure on was used in 10 patients, including 8 with hypopharygeal carcinomas, 1 with esophageal carcinoma and neck skin invasion and 1 with hypopharyngeal leiomyosarcoma, at the Otorhinolaryngology Hospital, the First Affiliated Hospital, Sun Yatsen University between December 2015 and June 2017. The sizes of the flaps were measured in (4-8) cm×(5-12) cm. Clinical indexes such as harvesting time and survival were recorded. Harvesting time for SCAIF ranged from 20 to 30 minutes, averaging 26 minutes. Nine flaps survived, one flap had partially necrosis. Functional outcomes were excellent and the donor sites were direct closed without complications. SCAIF is a versatile, reliable, and easily harvested flap, with good cosmetic and functional outcomes for reconstructing the defects of hypopharynx and upper esophagus.
[Mh] Termos MeSH primário: Carcinoma/cirurgia
Neoplasias Esofágicas/cirurgia
Esôfago/cirurgia
Neoplasias Hipofaríngeas/cirurgia
Hipofaringe/cirurgia
Procedimentos Cirúrgicos Reconstrutivos/métodos
Retalhos Cirúrgicos/transplante
[Mh] Termos MeSH secundário: Artérias
Seres Humanos
Leiomiossarcoma/cirurgia
Pescoço
Necrose
Neoplasias Cutâneas/cirurgia
Retalhos Cirúrgicos/irrigação sanguínea
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180125
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.1673-0860.2018.01.004


  7 / 7672 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29321523
[Au] Autor:Chudasama P; Mughal SS; Sanders MA; Hübschmann D; Chung I; Deeg KI; Wong SH; Rabe S; Hlevnjak M; Zapatka M; Ernst A; Kleinheinz K; Schlesner M; Sieverling L; Klink B; Schröck E; Hoogenboezem RM; Kasper B; Heilig CE; Egerer G; Wolf S; von Kalle C; Eils R; Stenzinger A; Weichert W; Glimm H; Gröschel S; Kopp HG; Omlor G; Lehner B; Bauer S; Schimmack S; Ulrich A; Mechtersheimer G; Rippe K; Brors B; Hutter B; Renner M; Hohenberger P; Scholl C; Fröhling S
[Ad] Endereço:Division of Translational Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
[Ti] Título:Integrative genomic and transcriptomic analysis of leiomyosarcoma.
[So] Source:Nat Commun;9(1):144, 2018 01 10.
[Is] ISSN:2041-1723
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Leiomyosarcoma (LMS) is an aggressive mesenchymal malignancy with few therapeutic options. The mechanisms underlying LMS development, including clinically actionable genetic vulnerabilities, are largely unknown. Here we show, using whole-exome and transcriptome sequencing, that LMS tumors are characterized by substantial mutational heterogeneity, near-universal inactivation of TP53 and RB1, widespread DNA copy number alterations including chromothripsis, and frequent whole-genome duplication. Furthermore, we detect alternative telomere lengthening in 78% of cases and identify recurrent alterations in telomere maintenance genes such as ATRX, RBL2, and SP100, providing insight into the genetic basis of this mechanism. Finally, most tumors display hallmarks of "BRCAness", including alterations in homologous recombination DNA repair genes, multiple structural rearrangements, and enrichment of specific mutational signatures, and cultured LMS cells are sensitive towards olaparib and cisplatin. This comprehensive study of LMS genomics has uncovered key biological features that may inform future experimental research and enable the design of novel therapies.
[Mh] Termos MeSH primário: Leiomiossarcoma/genética
Leiomiossarcoma/metabolismo
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Cromotripsia
Variações do Número de Cópias de DNA
Feminino
Duplicação Gênica
Perfilação da Expressão Gênica
Genes do Retinoblastoma
Genes p53
Genômica
Seres Humanos
Masculino
Meia-Idade
Mutação
Análise de Sequência de RNA
Homeostase do Telômero
Sequenciamento Completo do Exoma
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180112
[St] Status:MEDLINE
[do] DOI:10.1038/s41467-017-02602-0


  8 / 7672 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463949
[Au] Autor:Peters A; Sadecky AM; Winger DG; Guido RS; Lee TTM; Mansuria SM; Donnellan NM
[Ad] Endereço:*Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital of UPMC, Pittsburgh, PA; †Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR; and ‡Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA.
[Ti] Título:Characterization and Preoperative Risk Analysis of Leiomyosarcomas at a High-Volume Tertiary Care Center.
[So] Source:Int J Gynecol Cancer;27(6):1183-1190, 2017 Jul.
[Is] ISSN:1525-1438
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Uterine morcellation in minimally invasive surgery has recently come under scrutiny because of inadvertent dissemination of malignant tissue, including leiomyosarcomas commonly mistaken for fibroids. Identification of preoperative risk factors is crucial to ensure that oncologic care is delivered when suspicion for malignancy is high, while offering minimally invasive hysterectomies to the remaining patients. OBJECTIVES: The aim of this study was to characterize risk factors for uterine leiomyosarcomas by reviewing preoperative, intraoperative, and postoperative data with an emphasis on the presence of concurrent fibroids. METHODS: A retrospective case-control study of women undergoing hysterectomy with pathologic diagnosis of uterine leiomyosarcoma at a tertiary care center between January 2005 and April 2014. RESULTS: Thirty-one women were identified with leiomyosarcoma and matched to 124 controls. Cases with leiomyosarcoma were more likely to have undergone menopause and to present with larger uteri (19- vs 9-week sized), with the most common presenting complaint being a pelvic mass (35.5% vs 8.9%). Controls were ten times more likely to have undergone a tubal ligation (30.6% vs 3.2%). Endometrial sampling detected malignancy preoperatively in only 50% of cases. Leiomyosarcomas were more commonly present when pelvic masses were identified in addition to fibroids on preoperative imaging. Most leiomyosarcoma cases (77.4%) were performed by oncologists via an abdominal approach (83.9%), with only 2 of 31 leiomyosarcomas being morcellated. Comparative analysis of preoperative imaging and postoperative pathology showed that in patients with leiomyosarcoma, fibroids were misdiagnosed 58.1% of the time, and leiomyosarcomas arose directly from fibroids in only 6.5% of cases. CONCLUSIONS: Leiomyosarcoma risk factors include older age/postmenopausal status, enlarged uteri of greater than 10 weeks, and lack of previous tubal ligation. Preoperative testing failed to definitively identify leiomyosarcomas, although the presence of synchronous pelvic masses in fibroid uteri should raise clinical suspicion. Given the difficulty of preoperative identification, future efforts should focus on the development of safer minimally invasive techniques for uterine morcellation.
[Mh] Termos MeSH primário: Leiomiossarcoma/patologia
Leiomiossarcoma/cirurgia
Neoplasias Uterinas/patologia
Neoplasias Uterinas/cirurgia
[Mh] Termos MeSH secundário: Estudos de Casos e Controles
Feminino
Seres Humanos
Histerectomia/efeitos adversos
Histerectomia/métodos
Leiomioma/patologia
Leiomioma/cirurgia
Meia-Idade
Inoculação de Neoplasia
Cuidados Pós-Operatórios
Cuidados Pré-Operatórios
Estudos Retrospectivos
Medição de Risco
Centros de Atenção Terciária
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180206
[Lr] Data última revisão:
180206
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1097/IGC.0000000000000940


  9 / 7672 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29186204
[Au] Autor:Lopez G; Braggio D; Zewdu A; Casadei L; Batte K; Bid HK; Koller D; Yu P; Iwenofu OH; Strohecker A; Choy E; Lev D; Pollock R
[Ad] Endereço:Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States of America.
[Ti] Título:Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates.
[So] Source:PLoS One;12(11):e0188859, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Leiomyosarcoma (LMS) is a malignant soft tissue sarcoma (STS) with a dismal prognosis following metastatic disease. Chemotherapeutic intervention has demonstrated to have modest clinical efficacy with no curative potential in LMS patients. Previously, we demonstrated pan-HDAC inhibition to have a superior effect in various complex karyotypic sarcomas. In this study, our goal is to evaluate the therapeutic efficacy of mocetinostat alone and in combination with gemcitabine in LMS. Human leiomyosarcoma (LMS) cell lines were used for in vitro and in vivo studies. Compounds tested included the class I HDAC inhibitor, mocetinostat, and nucleoside analog, gemcitabine. MTS and clonogenic assays were used to evaluate the effect of mocetinostat on LMS cell growth. Cleaved caspase 3/7 analysis was used to determine the effects of mocetinostat on apoptosis. Compusyn software was used to determine in vitro synergy studies for the combination of mocetinostat plus gemcitabine. A LMS xenograft model in SCID mice was used to test the impact of mocetinostat alone, gemcitabine alone and the combination of mocetinostat plus gemcitabine. Mocetinostat abrogated LMS cell growth and clonogenic potential, and enhanced apoptosis in LMS cell lines. The combination of mocetinostat plus gemcitabine exhibited a synergistic effect in LMS cells in vitro. Similarly, mocetinostat combined with gemcitabine resulted in superior anti-LMS effects in vivo. Mocetinostat reduced the expression of gemcitabine-resistance markers RRM1, RRM2, and increased the expression of gemcitabine-sensitivity marker, hENT1, in LMS cells. LMS are aggressive, metastatic tumors with poor prognosis where effective therapeutic interventions are wanting. Our studies demonstrate the potential utility of mocetinostat combined with gemcitabine for the treatment of LMS.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Leiomiossarcoma/tratamento farmacológico
[Mh] Termos MeSH secundário: Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia
Apoptose/efeitos dos fármacos
Benzamidas/administração & dosagem
Divisão Celular/efeitos dos fármacos
Linhagem Celular Tumoral
Desoxicitidina/administração & dosagem
Desoxicitidina/análogos & derivados
Sinergismo Farmacológico
Seres Humanos
Leiomiossarcoma/patologia
Pirimidinas/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Benzamides); 0 (Pyrimidines); 0W860991D6 (Deoxycytidine); A6GWB8T96J (mocetinostat); B76N6SBZ8R (gemcitabine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180101
[Lr] Data última revisão:
180101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171130
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0188859


  10 / 7672 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29195579
[Au] Autor:Abdelhady K; Durgam S; Ernst L; Massad MG
[Ad] Endereço:Division of Cardiothoracic Surgery, Department of Surgery, The University of Illinois at Chicago, Chicago, Illinois. Electronic address: khaled1@uic.edu.
[Ti] Título:Primary Pulmonary Vein Leiomyosarcoma With Left Atrial Extension.
[So] Source:Semin Thorac Cardiovasc Surg;29(3):428-430, 2017 Autumn.
[Is] ISSN:1532-9488
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Leiomyosarcoma (LMS) is a mesenchymal tumor originating from the smooth muscle cells. LMS of the great vessels accounts for 60% of cases, with inferior vena cava being the most common site. Pulmonary vein LMS is an extremely rare subset that was first reported in 1939. LMS is an aggressive tumor, making surgical resection the treatment of choice. Herein, we present a rare case of pulmonary vein LMS extending into the left atrium, which was resected.
[Mh] Termos MeSH primário: Átrios do Coração/patologia
Leiomiossarcoma/patologia
Veias Pulmonares/patologia
Neoplasias Vasculares/patologia
[Mh] Termos MeSH secundário: Ecocardiografia
Feminino
Átrios do Coração/diagnóstico por imagem
Átrios do Coração/cirurgia
Seres Humanos
Leiomiossarcoma/diagnóstico por imagem
Leiomiossarcoma/cirurgia
Imagem por Ressonância Magnética
Meia-Idade
Invasividade Neoplásica
Veias Pulmonares/diagnóstico por imagem
Veias Pulmonares/cirurgia
Tomografia Computadorizada por Raios X
Resultado do Tratamento
Neoplasias Vasculares/diagnóstico por imagem
Neoplasias Vasculares/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171226
[Lr] Data última revisão:
171226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171203
[St] Status:MEDLINE



página 1 de 768 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde